Alain Thibault
Impact in
- Hematology top 2%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Cancer Research top 5%
- Cancer, Lipids, and Metabolism
Papers in
-
- Cancer, Hypoxia, and Metabolism 8
- Cancer, Lipids, and Metabolism 8
- Oncology 19
- Cancer Treatment and Pharmacology 7
- Co-authors
- Dvorit SamidMichael R. CooperA TompkinsCharles E. MyersWilliam D. FiggDonna HeadleeDavid VenzonMark A. Miller
- Journals
- Blood (6 papers)Cancer (4 papers)Journal of Clinical Oncology (4 papers)Annals of Oncology (3 papers)The Prostate (2 papers)
- Partner nations
- United StatesBelgiumCanada
In The Last Decade
Alain Thibault
48 papers receiving 2.4k citations
Peers
Comparison fields: 5 of 100
- Hematology 560
- Cancer Research 584
- Genetics 286
- Oncology 694
- Molecular Biology 1.2k
Countries citing papers authored by Alain Thibault
This map shows the geographic impact of Alain Thibault's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alain Thibault with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alain Thibault more than expected).
Fields of papers citing papers by Alain Thibault
This network shows the impact of papers produced by Alain Thibault. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alain Thibault. The network helps show where Alain Thibault may publish in the future.
Co-authors
The 25 scholars most cited alongside Alain Thibault, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 1 | |
| 2 | 2017 | 47 | |
| 3 | 2015 | 3 | |
| 4 | 2013 | 76 | |
| 5 | 2009 | 7 | |
| 6 | 2003 | 8 | |
| 7 | A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. | 2003 | 40 |
| 8 | A phase I, clinical and pharmacokinetic (PK) trial of the farnesyl transferase inhibitor (FTI) R115777 + docetaxel : a promising combination in patients (pts) with solid tumors | 2001 | 36 |
| 9 | 1997 | 2 | |
| 10 | 1996 | 23 | |
| 11 | 1996 | 100 | |
| 12 | 1996 | 1 | |
| 13 | 1995 | 63 | |
| 14 | 1995 | 40 | |
| 15 | 1995 | 53 | |
| 16 | 1995 | 110 | |
| 17 | 1994 | 9 | |
| 18 | 1994 | 13 | |
| 19 | 1991 | 108 | |
| 20 | [Antiinflammatory and analgesic properties of several enolates derived from acyl-butenolides]. | 1978 | 2 |
About Alain Thibault
Alain Thibault is a scholar working on Cancer Research, Oncology, Hematology, Genetics and Pulmonary and Respiratory Medicine, having authored 49 papers that have together received 2.5k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (9 papers), Cancer, Hypoxia, and Metabolism (8 papers), Cancer, Lipids, and Metabolism (8 papers), Cancer Treatment and Pharmacology (7 papers), Monoclonal and Polyclonal Antibodies Research (6 papers), Acute Myeloid Leukemia Research (5 papers), Lung Cancer Treatments and Mutations (4 papers) and Chronic Myeloid Leukemia Treatments (4 papers). The work is most often cited by research in Hematology (560 citations), Cancer Research (584 citations), Genetics (286 citations), Oncology (694 citations) and Molecular Biology (1.2k citations). Alain Thibault has collaborated with scholars based in United States, Belgium and Canada. Frequent co-authors include Dvorit Samid, Michael R. Cooper, A Tompkins, Charles E. Myers, William D. Figg, Donna Headlee, William D. Figg, David Venzon, Mark A. Miller and Raymond J. Hohl. Their work appears in journals such as Blood, Cancer, Journal of Clinical Oncology, Annals of Oncology and The Prostate.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.